Cellectis S.A [ALCLS] vs Inventiva S.A [IVA] Detailed Stock Comparison
Cellectis S.A
Euronext
Loading...
Inventiva S.A
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Cellectis S.A wins in 10 metrics, Inventiva S.A wins in 6 metrics, with 0 ties. Cellectis S.A appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Cellectis S.A | Inventiva S.A | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -5.88 | -0.94 | Cellectis S.A |
| Price-to-Book Ratio | 2.45 | -1.05 | Inventiva S.A |
| Debt-to-Equity Ratio | 40.92 | -1.70 | Inventiva S.A |
| PEG Ratio | -2.68 | -2.08 | Cellectis S.A |
| EV/EBITDA | -6.27 | -3.82 | Cellectis S.A |
| Profit Margin (TTM) | -93.00% | 0.00% | Inventiva S.A |
| Operating Margin (TTM) | -52.69% | -384.43% | Cellectis S.A |
| Return on Equity | -48.02% | 172.73% | Inventiva S.A |
| Return on Assets (TTM) | -7.43% | -63.60% | Cellectis S.A |
| Free Cash Flow (TTM) | $19.15M | $-86.26M | Cellectis S.A |
| 1-Year Return | 28.80% | 34.26% | Inventiva S.A |
| Price-to-Sales Ratio (TTM) | 3.84 | 28.71 | Cellectis S.A |
| Enterprise Value | $179.84M | $357.93M | Inventiva S.A |
| EV/Revenue Ratio | 3.29 | 25.40 | Cellectis S.A |
| Gross Profit Margin (TTM) | 85.50% | N/A | N/A |
| Revenue per Share (TTM) | $1 | $0 | Cellectis S.A |
| Earnings per Share (Diluted) | $-0.51 | $-3.08 | Cellectis S.A |
| Beta (Stock Volatility) | N/A | 0.62 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Cellectis S.A vs Inventiva S.A Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Cellectis S.A | -2.47% | -4.82% | 74.26% | 70.50% | 56.95% | 37.79% |
| Inventiva S.A | 1.05% | 3.94% | 5.45% | -7.35% | 27.75% | 37.44% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Cellectis S.A | 28.80% | -34.35% | -83.45% | -92.09% | -60.37% | -60.37% |
| Inventiva S.A | 34.26% | -45.28% | -70.88% | -65.02% | -65.02% | -65.02% |
Performance & Financial Health Analysis: Cellectis S.A vs Inventiva S.A
| Metric | ALCLS | IVA |
|---|---|---|
| Market Information | ||
| Market Cap | €243.88M | €404.66M |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 788,434 | 108,036 |
| 90 Day Avg. Volume | 412,272 | 62,815 |
| Last Close | €2.37 | €2.90 |
| 52 Week Range | €1.01 - €3.19 | €1.43 - €3.30 |
| % from 52W High | -25.82% | -12.12% |
| All-Time High | €41.95 (Nov 02, 2015) | €16.30 (Jan 18, 2021) |
| % from All-Time High | -94.35% | -82.21% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.92% | -0.30% |
| Quarterly Earnings Growth | 1.07% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | -0.93% | 0.00% |
| Operating Margin (TTM) | -0.53% | -3.84% |
| Return on Equity (TTM) | -0.48% | 1.73% |
| Debt to Equity (MRQ) | 40.92 | -1.70 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €0.98 | €-1.12 |
| Cash per Share (MRQ) | €0.61 | €1.01 |
| Operating Cash Flow (TTM) | €-28,777,597 | €-85,928,000 |
| Levered Free Cash Flow (TTM) | €-24,538,865 | €-56,252,248 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Cellectis S.A vs Inventiva S.A
| Metric | ALCLS | IVA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -5.88 | -0.94 |
| Forward P/E | -2.68 | -2.08 |
| PEG Ratio | -2.68 | -2.08 |
| Price to Sales (TTM) | 3.84 | 28.71 |
| Price to Book (MRQ) | 2.45 | -1.05 |
| Market Capitalization | ||
| Market Capitalization | €243.88M | €404.66M |
| Enterprise Value | €179.84M | €357.93M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.29 | 25.40 |
| Enterprise to EBITDA | -6.27 | -3.82 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.62 |
| Book Value per Share (MRQ) | €0.98 | €-1.12 |
Financial Statements Comparison: Cellectis S.A vs Inventiva S.A
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ALCLS | IVA |
|---|---|---|
| Revenue/Sales | €10.66M | €65,000 |
| Cost of Goods Sold | €2.02M | N/A |
| Gross Profit | €8.64M | N/A |
| Research & Development | €21.93M | €11.91M |
| Operating Income (EBIT) | €-14.18M | €-13.67M |
| EBITDA | €-6.34M | €-13.43M |
| Pre-Tax Income | €-18.13M | €-14.27M |
| Income Tax | €0 | €21,000 |
| Net Income (Profit) | €-18.13M | €-14.30M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ALCLS | IVA |
|---|---|---|
| Cash & Equivalents | €127.64M | €96.56M |
| Total Current Assets | €271.82M | €111.51M |
| Total Current Liabilities | €162.57M | €120.73M |
| Long-Term Debt | €78.87M | €48.46M |
| Total Shareholders Equity | €116.20M | €-106.65M |
| Retained Earnings | €-347.69M | €-184.21M |
| Property, Plant & Equipment | €93.92M | €10.72M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ALCLS | IVA |
|---|---|---|
| Operating Cash Flow | €-18.57M | €-24.55M |
| Capital Expenditures | €-395,000 | €-63,000 |
| Free Cash Flow | €-17.56M | €-12.13M |
| Debt Repayment | €-3.94M | €-1,000 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ALCLS | IVA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 788,434 | 108,036 |
| Average Daily Volume (90 Day) | 412,272 | 62,815 |
| Shares Outstanding | 72.09M | 95.66M |
| Float Shares | 53.18M | 53.99M |
| % Held by Insiders | 0.48% | 0.08% |
| % Held by Institutions | 0.19% | 0.64% |
Dividend Analysis & Yield Comparison: Cellectis S.A vs Inventiva S.A
| Metric | ALCLS | IVA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |